Last reviewed · How we verify
NCT03231930
Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC) Pilot Study
NA trial testing OraQuick HCV Ab test in Hepatitis C in 174 participants. Completed in 17 May 2018.
1 November 2017
Quick facts
| Lead sponsor | Macfarlane Burnet Institute for Medical Research and Public Health Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 174 |
| Start date | 29 June 2017 |
| Primary completion | 1 November 2017 |
| Estimated completion | 17 May 2018 |
| Sites | 3 locations across Australia |
Drugs / interventions tested
- OraQuick HCV Ab test
- Xpert HCV viral load test
Conditions studied
- Hepatitis C — all drugs for Hepatitis C →
Sponsor
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Who can join
18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Rapid-EC pilot study will determine feasibility of providing rapid point-of-care (POC) testing for HCV in community clinics, and whether the availability of POC testing increases uptake of testing, engagement in care and completion of treatment among people who inject drugs. The POC tests being utilised in this study are the OraQuick mouth swab test for the presence of HCV antibodies, and the Xpert HCV RNA viral load test using serum.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03231930
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C
Currently open trials in the same condition.
- NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
- NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
- NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
- NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
- NCT05208697 — Tele-Harm Reduction · NA · active not recruiting
Other Macfarlane Burnet Institute for Medical Research and Public Health Ltd trials
Trials by the same sponsor.
- NCT05874271 — Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea · NA · completed
- NCT05264558 — Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% · Phase 4 · completed
- NCT07337382 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 · active not recruiting
- NCT05323799 — The Optimising Isolation, Quarantine and Distancing Study for COVID-19 (Optimise) · unknown
- NCT04510246 — Link Hepatitis C Notifications to Treatment in Tasmania · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03231930 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- Last refreshed: 15 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03231930.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing